Gilead Sciences Appoints Flavius Martin, MD as Executive Vice President, Research

William ("Bill") Lee, PhD to Retire After 30 Years at Gilead –

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Flavius Martin, MD will join the company as Executive Vice President, Research, and will become a member of the company's senior leadership team, reporting to Chairman and Chief Executive Officer Daniel O'Day. Dr. Martin will assume responsibility for Gilead's research organization effective April 12, 2021. Bill Lee, PhD, is retiring from Gilead after three decades.

Dr. Martin brings to his new role significant experience overseeing industry-leading research, with particular expertise in oncology and inflammation. He joins Gilead from Amgen, Inc., where he most recently served as Vice President, Research Biology, leading discovery for Oncology, Inflammation and Cardiometabolic Research. He was also the site-head for Amgen South San Francisco. Prior to Amgen, Dr. Martin worked as a scientist and leader at Genentech, Inc.

"Flavius brings decades of experience in early drug discovery research and identification of promising therapeutic candidates," said Mr. O'Day. "He has deep scientific expertise across therapeutic areas and has led the creation of high-quality portfolios in prior roles. I am delighted to welcome him to Gilead as we continue to expand and diversify our portfolio of new medicines."

Dr. Martin received his MD at the University of Medicine and Pharmacy Timisoara, Romania. He completed his postdoctoral training at the University of Alabama at Birmingham in the Division of Developmental and Clinical Immunology. He has published numerous papers on the role of immune cells in driving inflammatory diseases and cancer, and holds a number of patents related to his discoveries.

"Gilead has outstanding research and clinical development programs across Virology, Immunology and Oncology, and I am tremendously excited to be joining an organization with such a deep and talented scientific core," commented Dr. Martin. "Throughout my career, I have been focused on translating scientific discoveries into the development of potential new therapies with the goal of helping people with unmet medical needs. I look forward to pursuing this mission together with the talented team at Gilead."

Dr. Lee joined Gilead in 1991. Over his 30-year career with the company, he has overseen research programs across multiple therapeutic areas and has led the advancement of numerous therapies from early-stage research into clinical development. His expertise contributed to the discovery of medicines and the identification of external partnerships.

"Bill's contributions over three decades have allowed Gilead to bring important new medicines to patients around the world," said Mr. O'Day. "I am grateful to Bill for the high bar he has set for Gilead's research organization and the commitment he demonstrated pursuing scientific advancements that transformed care for people with serious diseases."

About Gilead Sciences

Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis and cancer. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California.

For more information on Gilead Sciences, please visit the company's website at www.gilead.com , follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.

Jacquie Ross, Investors
(650) 358-1054

Marni Kottle, Media
(650) 522-5388

News Provided by Business Wire via QuoteMedia

The Conversation (0)
  BPH Global Ltd

120-Day Business Development Plan

The Board of BPH Global Ltd (ASX: BP8) (Company) announces that the Company’s CEO Matthew Leonard and CFO Chow Yee Koh are currently travelling in Malaysia and China for a series of meetings over a 2–3- week period commencing last week. The CEO and CFO will be joined by China-based Company Director Michael Huang for strategic meetings in Malaysia and China.

Keep reading...Show less
  BPH Global Ltd

BP8 to Expand Seaweed R&D Activities into Essential Mineral Extraction Utilising AI Search Technology; Carbon Credits

The Board of BPH Global Ltd (ASX: BP8) (Company) is pleased to announce that the Company is expanding the nature of its business to include the following projects:

Keep reading...Show less
Sirona Biochem Receives Commercial-Grade GlycoProteMim Based Anti-Aging Serum Formulations

Sirona Biochem Receives Commercial-Grade GlycoProteMim Based Anti-Aging Serum Formulations

Sirona Biochem Corp . (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (" Sirona " or the " Company ") announces a significant achievement in its quest to transform the skincare industry. Its subsidiary, TFChem, has successfully received formulations for its eagerly awaited GlycoProteMim™ based anti-aging serum from its formulation partner, Global Beauty Consulting (GBC). This marks a crucial step in Sirona Biochem's plan to offer innovative skincare solutions.

The chosen formulation will not only define the brand but also lay the foundation for a broader range of products. The team is in the process of selecting the precise formulation that will undergo standard safety evaluations and be used in the upcoming clinical trial. This is in preparation for the planned product launch in early 2025, ensuring compliance with regulatory standards in the European, US, and Canadian markets.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
double helix molecule with word "etf"

5 Small Biotech ETFs to Watch (Updated 2024)

Thanks to exchange-traded funds (ETFs), investors don’t have to be tied to one specific stock. Biotech ETFs allow market participants to gain leverage in multiple biotech companies via one investment vehicle.

The life science sector can certainly be risky, and ETFs are a good way to enter more safely than by investing in standalone stocks. A key advantage is that even if one company in the ETF takes a hit, the impact will be less direct.

Below the Investing News Network takes a look at five small biotech ETFs for investors to consider. They were selected using ETFdb.com, and their total assets under management (AUM) were under US$100 million as of March 8, 2024. All other figures were also current as of that date. Read on to learn more about these investment vehicles.

Keep reading...Show less

AMGEN PRESENTS NEW RESEARCH ON OTEZLA® AT AAD 2024

SPROUT 52-Week Data Demonstrate Durable Response and Consistent Safety Profile of Oral Otezla in Children with Moderate to Severe Plaque Psoriasis

Late-Breaking Phase 3 Study of Otezla in Palmoplantar Pustulosis Achieves Primary and Secondary Endpoints at 16 Weeks

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
Collage with hands holding shiny DNA molecule on blue background.

5 Biggest Biotechnology ETFs in 2024

Investing in the biotech industry can be a long road to gains given the sector’s volatility.

Even with a good understanding of the system, no one can predict which treatment, device or therapy will give the biggest return, making biotech exchange-traded funds (ETFs) a more secure option than individual biotech stocks.

An ETF is a relatively safe investment route that can minimize losses while offering exposure to multiple companies instead of focusing on the gains and losses of a single biotech stock. With that in mind, here’s a brief look at the five top biotechnology ETFs by total assets. Data was sourced from ETFdb.com on March 1, 2024, and all data was current as of that time.

Keep reading...Show less

Latest Press Releases

Related News

×